Want to see PURE full AI Analyst Report?
Top Page
Pure Bioscience
(OTC:PURE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.06
▼(-26.25% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily held down by weak financial performance: persistent losses, negative equity, and ongoing cash burn with added uncertainty from reported data anomalies. Technicals provide only modest support due to mixed trend signals despite improving momentum. Valuation remains unattractive/unclear because losses drive a negative P/E and there is no dividend support.
Positive Factors
Revenue Growth
Strong recent sales growth and a multi-year rebound indicate improving customer adoption and market reach. If sustained, this growth can provide the scale needed to improve operating leverage and support future profitability.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that revenue growth has not yet translated into a viable earnings model. Continued negative margins could constrain reinvestment, weaken financing access, and delay the path to self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong recent sales growth and a multi-year rebound indicate improving customer adoption and market reach. If sustained, this growth can provide the scale needed to improve operating leverage and support future profitability.
Read all positive factors
Pure Bioscience (PURE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.98M
Dividend YieldN/A
Average Volume (3M)53.72K
Price to Earnings (P/E)―
Beta (1Y)-0.65
Revenue Growth26.67%
EPS Growth21.43%
CountryUS
Employees12
SectorConsumer Defensive
Sector Strength42
IndustryChemicals
Share Statistics
EPS (TTM)-0.02
Shares Outstanding130,017,560
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.96
Price to Sales (P/S)4.56
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pure Bioscience Business Overview & Revenue Model
Company Description
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform...
How the Company Makes Money
Pure Bioscience makes money primarily by selling products based on its SDC antimicrobial/disinfectant technology. Revenue is generated through the commercial distribution of finished disinfectant and sanitation products (and potentially through su...
Pure Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.42M | 2.20M | 1.96M | 1.88M | 1.85M | 3.93M |
| Gross Profit | 1.30B | 1.30M | 1.15M | 971.00K | 1.00M | 2.08M |
| EBITDA | 185.00K | -2.10M | -3.05M | -3.83M | -3.27M | -2.14M |
| Net Income | -2.21M | -2.40M | -3.35M | -3.96M | -3.50M | -2.32M |
Balance Sheet | ||||||
| Total Assets | 1.56M | 1.06M | 818.00K | 1.82M | 4.48M | 4.30M |
| Cash, Cash Equivalents and Short-Term Investments | 983.00K | 334.00M | 349.00K | 1.09M | 3.39M | 2.39M |
| Total Debt | 6.50M | 523.60K | 2.95M | 1.02M | 0.00 | 239.00K |
| Total Liabilities | 7.40M | 6.17M | 3.68M | 1.55M | 575.00K | 970.00K |
| Stockholders Equity | -5.84M | -5.12M | -2.86M | 272.00K | 3.91M | 3.33M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -2.02B | -2.53M | -3.31M | -2.50M | -1.69M |
| Operating Cash Flow | -1.78M | -2.02B | -2.53M | -3.28M | -2.42M | -1.17M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -33.00K | -81.00K | -521.00K |
| Financing Cash Flow | 2.22M | 2.00B | 1.78M | 1.01M | 3.50M | 239.00K |
Pure Bioscience Risk Analysis
Pure Bioscience disclosed 39 risk factors in its most recent earnings report. Pure Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pure Bioscience Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $32.73M | 13.24 | 22.24% | 6.56% | 3.23% | -3.58% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | $7.58M | 1.03 | 1.71% | 4.07% | 77.22% | -89.32% | |
49 Neutral | $12.08M | -1.62 | -2383.34% | ― | -4.97% | -91.06% | |
49 Neutral | $5.47M | -0.02 | -24.71% | ― | -10.67% | -83.85% | |
46 Neutral | $44.41M | -5.06 | -83.49% | ― | -14.25% | 66.08% | |
45 Neutral | $7.98M | -3.05 | 127.81% | ― | 26.67% | 21.43% |
* Consumer Defensive Sector Average
PURE
Pure Bioscience
0.06
-0.04
-39.00%
MTEX
Mannatech
6.32
-2.01
-24.13%
UG
United-Guardian
7.15
-0.32
-4.35%
TANH
Tantech Holdings
0.38
-1.74
-82.08%
GROV
Grove Collaborative Holdings
0.98
-0.57
-36.77%
TKLF
Yoshitsu Co. Ltd. Sponsored ADR
1.75
-1.79
-50.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.